BG105782A - Reverse hydroxamate inhibitors of matrix metalloproteinases - Google Patents

Reverse hydroxamate inhibitors of matrix metalloproteinases

Info

Publication number: BG105782A
Authority: BG; Bulgaria
Prior art keywords: matrix metalloproteinases; hydroxamate inhibitors; reverse hydroxamate; inhibitors; matrix metalloproteinase
Prior art date: 1999-01-27

Application number

BG105782A

Other languages

Bulgarian (bg)

English (en)

Inventor

Michael Curtin

Yujia Dai

Steven DAVIDSEN

Howard HEYMAN

James Holmes

Michael MICHAELIDES

Douglas STEINMAN

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-27

Filing date

2001-08-03

Publication date

2002-04-30

2001-08-03 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2002-04-30 Publication of BG105782A publication Critical patent/BG105782A/xx

Links

102000002274 Matrix Metalloproteinases Human genes 0.000 title abstract 3
108010000684 Matrix Metalloproteinases Proteins 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title 1
230000002401 inhibitory effect Effects 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003771 matrix metalloproteinase inhibitor Substances 0.000 abstract 1
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Furan Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BG105782A 1999-01-27 2001-08-03 Reverse hydroxamate inhibitors of matrix metalloproteinases BG105782A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23908799A	1999-01-27	1999-01-27
PCT/US2000/002038 WO2000044739A1 (en)	1999-01-27	2000-01-27	Reverse hydroxamate inhibitors of matrix metalloproteinases

Publications (1)

Publication Number	Publication Date
BG105782A true BG105782A (en)	2002-04-30

Family

ID=22900549

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG105782A BG105782A (en)	1999-01-27	2001-08-03	Reverse hydroxamate inhibitors of matrix metalloproteinases

Country Status (28)

Country	Link
US (1)	US20020007060A1 (de)
EP (1)	EP1147101B1 (de)
JP (1)	JP4718686B2 (de)
KR (1)	KR100748010B1 (de)
CN (1)	CN1222519C (de)
AR (1)	AR029329A1 (de)
AT (1)	ATE228122T1 (de)
AU (1)	AU764383B2 (de)
BG (1)	BG105782A (de)
BR (1)	BR0007278A (de)
CA (1)	CA2358951C (de)
CO (1)	CO5150194A1 (de)
CZ (1)	CZ20012591A3 (de)
DE (1)	DE60000819T2 (de)
DK (1)	DK1147101T3 (de)
ES (1)	ES2187443T3 (de)
HK (1)	HK1043115A1 (de)
HU (1)	HUP0105477A2 (de)
IL (1)	IL143713A0 (de)
NO (1)	NO20013669L (de)
NZ (1)	NZ512372A (de)
PL (1)	PL349771A1 (de)
PT (1)	PT1147101E (de)
SK (1)	SK10582001A3 (de)
TR (1)	TR200102159T2 (de)
TW (1)	TWI225486B (de)
WO (1)	WO2000044739A1 (de)
ZA (1)	ZA200104979B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9923078D0 (en) *	1999-09-29	1999-12-01	Phytopharm Plc	Sapogenin derivatives and their use
AU2001298065A1 (en) *	2001-01-12	2003-09-02	Abbott Laboratories	Process for the preparation of matrix metalloproteinase inhibitors
EP1431285B1 (de)	2001-09-07	2009-01-07	Kaken Pharmaceutical Co., Ltd.	Reverse hydroxamsäurederivate
EP1896404B1 (de) *	2005-06-27	2014-09-17	Nabriva Therapeutics AG	Pleuromutilinderivate mit einer hydroxyamino- oder acyloxyaminocycloalkylgruppe
EP2234608A2 (de)	2007-12-11	2010-10-06	Viamet Pharmaceuticals, Inc.	Metalloenzymhemmer mit metallbindenden teilen in kombination mit targeting-teilen
WO2015107139A1 (en)	2014-01-17	2015-07-23	Proyecto De Biomedicina Cima, S.L.	Compounds for use as antifibrinolytic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0780386T3 (da) *	1995-12-20	2003-02-03	Hoffmann La Roche	Matrixmetalloproteaseinhibitorer

2000
- 2000-01-25 CO CO00003867A patent/CO5150194A1/es unknown
- 2000-01-26 AR ARP000100349A patent/AR029329A1/es not_active Application Discontinuation
- 2000-01-27 AU AU27391/00A patent/AU764383B2/en not_active Ceased
- 2000-01-27 DK DK00905758T patent/DK1147101T3/da active
- 2000-01-27 HU HU0105477A patent/HUP0105477A2/hu unknown
- 2000-01-27 PT PT00905758T patent/PT1147101E/pt unknown
- 2000-01-27 CA CA002358951A patent/CA2358951C/en not_active Expired - Fee Related
- 2000-01-27 AT AT00905758T patent/ATE228122T1/de not_active IP Right Cessation
- 2000-01-27 KR KR1020017009393A patent/KR100748010B1/ko not_active Expired - Fee Related
- 2000-01-27 WO PCT/US2000/002038 patent/WO2000044739A1/en not_active Ceased
- 2000-01-27 PL PL00349771A patent/PL349771A1/xx not_active Application Discontinuation
- 2000-01-27 IL IL14371300A patent/IL143713A0/xx unknown
- 2000-01-27 DE DE60000819T patent/DE60000819T2/de not_active Expired - Lifetime
- 2000-01-27 SK SK1058-2001A patent/SK10582001A3/sk unknown
- 2000-01-27 ES ES00905758T patent/ES2187443T3/es not_active Expired - Lifetime
- 2000-01-27 JP JP2000595995A patent/JP4718686B2/ja not_active Expired - Fee Related
- 2000-01-27 CN CNB008032378A patent/CN1222519C/zh not_active Expired - Fee Related
- 2000-01-27 HK HK02102947.8A patent/HK1043115A1/zh unknown
- 2000-01-27 TR TR2001/02159T patent/TR200102159T2/xx unknown
- 2000-01-27 BR BR0007278-8A patent/BR0007278A/pt not_active Application Discontinuation
- 2000-01-27 CZ CZ20012591A patent/CZ20012591A3/cs unknown
- 2000-01-27 EP EP00905758A patent/EP1147101B1/de not_active Expired - Lifetime
- 2000-01-27 NZ NZ512372A patent/NZ512372A/xx unknown
- 2000-02-25 TW TW089101383A patent/TWI225486B/zh not_active IP Right Cessation
2001
- 2001-06-18 ZA ZA200104979A patent/ZA200104979B/en unknown
- 2001-07-16 US US09/905,242 patent/US20020007060A1/en not_active Abandoned
- 2001-07-26 NO NO20013669A patent/NO20013669L/no not_active Application Discontinuation
- 2001-08-03 BG BG105782A patent/BG105782A/xx unknown

Also Published As

Publication number	Publication date
JP2002535398A (ja)	2002-10-22
HUP0105477A2 (hu)	2002-05-29
SK10582001A3 (sk)	2001-12-03
CN1222519C (zh)	2005-10-12
CZ20012591A3 (cs)	2001-12-12
ATE228122T1 (de)	2002-12-15
AU764383B2 (en)	2003-08-14
DK1147101T3 (da)	2003-03-10
CO5150194A1 (es)	2002-04-29
ES2187443T3 (es)	2003-06-16
PL349771A1 (en)	2002-09-09
JP4718686B2 (ja)	2011-07-06
TR200102159T2 (tr)	2001-12-21
CN1339032A (zh)	2002-03-06
AU2739100A (en)	2000-08-18
EP1147101A1 (de)	2001-10-24
KR100748010B1 (ko)	2007-08-09
CA2358951A1 (en)	2000-08-03
ZA200104979B (en)	2002-09-18
NO20013669D0 (no)	2001-07-26
DE60000819D1 (de)	2003-01-02
US20020007060A1 (en)	2002-01-17
DE60000819T2 (de)	2003-09-04
NZ512372A (en)	2003-01-31
IL143713A0 (en)	2002-04-21
CA2358951C (en)	2009-10-20
AR029329A1 (es)	2003-06-25
PT1147101E (pt)	2003-04-30
KR20010101709A (ko)	2001-11-14
BR0007278A (pt)	2001-11-27
HK1043115A1 (zh)	2002-09-06
WO2000044739A1 (en)	2000-08-03
NO20013669L (no)	2001-09-27
EP1147101B1 (de)	2002-11-20
TWI225486B (en)	2004-12-21

Publication	Publication Date	Title
IL133369A0 (en)	2001-04-30	Reverse hydroxamate inhibitors of matrix metalloproteinases
GB9919776D0 (en)	1999-10-27	Compoujnds
NZ516562A (en)	2003-06-30	Pyrimidine-2,4,6-trione metalloproteinase inhibitors
MY136133A (en)	2008-08-29	New mandelic acid derivatives and their use as thrombin inhibitors
MX9804623A (es)	1998-10-31	Precursores inactivos de farmacos inhibidores de trombina.
GEP20032920B (en)	2003-03-25	Inhibitors of Phospholipase Enzymes
CA2260337A1 (en)	1999-07-27	Therapeutic agents
AU5414000A (en)	2001-01-02	Compounds
SE9602646D0 (sv)	1996-07-04	Pharmaceutically-useful compounds
GB0030305D0 (en)	2001-01-24	Compounds
CA2294059A1 (en)	1998-12-23	New amidino derivatives and their use as thrombin inhibitors
AU2220702A (en)	2002-06-24	Serine protease inhibitors
NZ331484A (en)	2000-01-28	Serine protease inhibitors having an alkynylamino side chain for use in treatment of thrombin related diseases
ATE235462T1 (de)	2003-04-15	Metalloproteinase-inhibitoren
PL348972A1 (en)	2002-06-17	New amidino derivatives and their use as thrombin inhibitors
MY128164A (en)	2007-01-31	Compounds
BG104575A (en)	2001-02-28	Matrix metalloprotease inhibitors
GB2324091A (en)	1998-10-14	Metalloproteinase inhibitors
IL154077A0 (en)	2003-07-31	New amidino derivatives and their use as thrombin inhibitors
HK1043115A1 (zh)	2002-09-06	矩阵金属蛋白酶反异羟肟酸盐抑制剂
MY133842A (en)	2007-11-30	Sodium-hydrogen exchanger type 1 inhibitor.
MXPA05000517A (es)	2005-03-23	Derivados de sulfonilpiperidina que contienen una porcion alquenilo o alquinilo para uso como inhibidores de metaloproteinasas de matriz.
DE60012208D1 (de)	2004-08-19	Type 1 inhibitorkristalle als inhibitoren des natrium-protonen austauschs